https://www.selleckchem.com/pr....oducts/chloroquine.h
Results 27 patients had 18F-FDG-PET/CT imaging at baseline and after at least 4 cycles pembrolizumab. Median PFS and OS were 3.4 and 15.1 months, respectively. Response rate (RR) was 7%, 7%, 30%, and 30% based on RECIST v1.1, mRECIST, PERCISTSULpeak, and PERCISTMTV response criteria, respectively. Response according to PERCISTMTV predicted prolonged OS or PFS (P less then 0.01), whereas all other imaging criteria and PD-L1 expression did not. Conclusion 18F-FDG PET metabolic volume response predicts survival in patients with maligna
Like
Comment
Share
